Prostate Cell News Volume 11.13 | Apr 17 2020

TOP STORY

Prostate-Specific Antigen Dynamics Predict Individual Responses to Intermittent Androgen Deprivation

Researchers simulated prostate-specific antigen dynamics, with enrichment of prostate cancer stem-like cells during treatment as a plausible mechanism of resistance evolution. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

CCL5 Derived from Tumor-Associated Macrophages Promotes Prostate Cancer Stem Cells and Metastasis via Activating β-Catenin/STAT3 Signaling

Scientists demonstrated that tumor-associated macrophage-secreted CCL5 could significantly promote the migration, invasion, epithelial-mesenchymal transition of prostate cancer cells as well as the self-renewal of prostate cancer stem cells in vitro. [Cell Death Dis] Full Article

Caveolin-1 Regulates the ASMase/Ceramide-Mediated Radiation Response of Endothelial Cells in the Context of Tumor-Stroma Interactions

Caveolin-1 deficient endothelial cell increased the growth delay of LNCaP and PC3 prostate cancer cells upon radiation treatment in direct 3D spheroid co-cultures. Exogenous C6 and C16 ceramide treatment in parallel increased the growth delay of prostate cancer spheroids and induced prostate cancer cell apoptosis. [Cell Death Dis] Full Article

Emerging Therapeutic Activity of Davallia formosana on Prostate Cancer Cells through Coordinated Blockade of Lipogenesis and Androgen Receptor Expression

DF ethanol extract (DFE) suppressed proliferation, migration, and invasion in prostate cancer cells. DFE decreased androgen receptor and prostate-specific antigen expression in prostate cancer cells. [Cancers] Full Article

Metabolically Stable Diphenylamine Derivatives Suppress Androgen Receptor and BET Protein in Prostate Cancer

Scientists developed several diphenylamine derivatives and identified compound 7d that disrupted the functions of androgen receptor and bromodomain and extra-terminal domain (BET) family in prostate cancer and exhibited favorable metabolic stability in vitro and high drug exposure in vivo. [Biochem Pharmacol] Abstract

Effects of Orthotopic Implantation of Rat Prostate Tumor Cells upon Components of the N-Acylethanolamine and Monoacylglycerol Signaling Systems: An mRNA Study

AT1 cells in culture expressed Faah, coding for the N-acylethanolamine (NAE) hydrolytic enzyme fatty acid amide hydrolase, at much lower levels than Naaa. However, the ability of the intact cells to hydrolyse the NAE arachidonoylethanolamide was inhibited by an inhibitor of FAAH, but not of NAAA. [Sci Rep] Full Article

FAM46C Inhibits Cell Proliferation and Cell Cycle Progression and Promotes Apoptosis through PTEN/AKT Signaling Pathway and Is Associated with Chemosensitivity in Prostate Cancer

FAM46C knockdown in 22RV1 and DU145 cells significantly inhibited apoptosis and promoted cell proliferation and cell cycle progression as well as activation of AKT. [Aging (Albany NY)] Full Article

miR-30a Inhibits Androgen-Independent Growth of Prostate Cancer via Targeting MYBL2, FOXD1, and SOX4

Regulation of cell proliferation and colony formation rates by miR-30a were tested using prostate cancer cell models. Xenograft models were used to measure the regulation of prostate tumor growth by miR-30a. [Prostate] Abstract

Integrative Analysis of AR-Mediated Transcriptional Regulatory Network Reveals IRF1 as an Inhibitor of Prostate Cancer Progression

The 24 core transcriptional factors and core transcriptional regulatory network participate in regulating prostate cancer cell proliferation, RNA splicing, and cancer metabolism. Further validations showed that androgen receptor (AR) signaling could promote glycolysis via inducing glycolytic enzymes in prostate cancer cells. [Prostate] Abstract

Impact of Nuclear YAP1 Expression in Residual Cancer after Neoadjuvant Chemohormonal Therapy with Docetaxel for High-Risk Localized Prostate Cancer

A tissue microarray with 203 cores from 70 high-risk localized prostate cancer tissues was performed to assess steroid receptor and Hippo pathway protein expressions. Nuclear YAP expression was higher in 22RV-1-DR than in parental 22Rv-1 and YAP1 knockdown suppressed cell proliferation of 22Rv1-DR. [BMC Cancer] Full Article

Synergistic Anti-Tumor Effects of Liraglutide, a Glucagon-Like Peptide-1 Receptor Agonist, Along with Docetaxel on LNCaP Prostate Cancer Cell Line

The authors investigated whether Liraglutide, a glucagon like peptide-1 receptor agonist, could reinforce the effect of docetaxel on LNCaP prostate cancer cell line. [Eur J Pharmacol] Abstract

^99mTc-(EDDA/Tricine)-HYNIC-GnRH Analogue as a Potential Imaging Probe for Diagnosis of Prostate Cancer

Two human prostate cancer cell lines LN-CaP and DU-145 were used for cellular experiments. The binding specificity and affinity of radiopeptide for LN-CaP were superior to DU-145 cells. [Chem Biol Drug Des] Abstract

Ectopic Expression of miR-532-3p Suppresses Bone Metastasis of Prostate Cancer Cells via Inactivating NF-κB Signaling

Upregulating miR-532-3p inhibited invasion and migration abilities of prostate cancer cells in vitro, while silencing miR-532-3p yielded an opposite effect on invasion and migration abilities of prostate cancer cells. [Mol Ther Oncolytics] Abstract

Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News.

Flavonoids as Epigenetic Modulators for Prostate Cancer Prevention

Scientists give an overview the most recent evidence of the antitumoral effects exerted by dietary flavonoids, with a special focus on their epigenetic action in prostate cancer. [Nutrients] Full Article

Targeted Radionuclide Therapy of Prostate Cancer-From Basic Research to Clinical Perspectives

The authors summarize the recent advances in research on identification of prostate tissue-specific antigens for targeted therapy, generation of highly specific and selective molecules targeting these antigens. [Molecules] Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.

Crown Bioscience Expands PDX Collection with Acquisition of Unique Models from Leading Academic Medical Centers

Crown Bioscience, Inc. announced the strategic expansion of their PDX collection through new agreements with CoMotion at the University of Washington and Dana-Farber Cancer Institute. These agreements will provide highly needed prostate cancer and lymphoma models, respectively, to the oncology drug development community. [Crown Bioscience, Inc.] Press Release

First Patient Treated with Leronlimab in Phase IIb/III Trial for COVID-19

CytoDyn, Inc. announced it has treated the first patient in its Phase II basket trial for 22 solid cancer tumors. [CytoDyn, Inc.] Press Release

WHO’s Tedros, Expressing ‘Regret’ over Trump Move to Cut Funding, Says His Focus Is on ‘Saving Lives’

The head of the World Health Organization expressed “regret” that President Trump intends to cut off US funding to the agency over its handling of the coronavirus, but pointedly avoided criticizing the US move. [STAT News] Editorial

Ending Coronavirus Lockdowns Will Be a Dangerous Process of Trial and Error

After the novel coronavirus made its way from China around the world, one country after another adopted harsh measures to stop SARS-CoV-2 from spreading and overwhelming hospitals. They have hit the pause button on their economies and their citizens’ lives, stopping sports events, religious services, and other social gatherings. [ScienceInsider] Editorial

In light of COVID-19, many conferences are being cancelled or postponed. As such:

We are suspending new event postings in our newsletters and on Twitter.
We will strive to keep our current event listings updated with event status.
We encourage you to visit event sites directly for updates.

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Researcher – Translational Cancer Research (Johannes Kepler University of Linz)

Postdoctoral Associate – Urology Cancer Related Research (University of Miami Health System)

Postdoctoral Associate – Leydig Stem Cell Research (University of Miami Health System)

Associate Professor – Cancer Biology (University of Cincinnati)

Postdoctoral Scholar – Tumor Metabolism and DNA Repair (The Ohio State University)

Postdoctoral Position – Cancer Cell Biology and Drug Discovery (University of Luxembourg)

Postdoctoral Research Fellow – Molecular Oncology (Genentech)

Postdoctoral Fellow – Solid Tumor Microenvironment Research (H. Lee Moffitt Cancer Center & Research Institute)

Postdoctoral Position – Prostate Cancer (University of Washington)

Head – Single Cell Research (Sloan Kettering Institute)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.